
Silexion Therapeutics Corp. (NASDAQ:SLXN) stock is trading higher on Thursday, with a session volume of 16.87 million compared to the average volume of 74.2 thousand as per data from Benzinga Pro.
The company released new preclinical data demonstrating that subcutaneously administered SIL204 successfully reaches all primary sites of pancreatic cancer metastasis and shows anti-tumor activity.